Actively Recruiting
Nuclear Imaging for Subtype Diagnosis of Primary Aldosteronism
Led by University of Calgary · Updated on 2024-07-24
30
Participants Needed
1
Research Sites
182 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is to evaluate the accuracy of a novel radiopharmaceutical tracer, para-chloro-2-\[18F\]fluoroethyl etomidate (CETO), used with positron emission tomography (PET) and computed tomography (CT), as a way to subtype unilateral vs. bilateral forms of Primary Aldosteronism, compared to AVS as a reference gold standard.
CONDITIONS
Official Title
Nuclear Imaging for Subtype Diagnosis of Primary Aldosteronism
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Individuals with hypertension
- Individuals with an elevated screening adrenal renin ratio (ARR)
- Individuals with or without spontaneous or diuretic-induced hypokalemia
- Individuals with one or more adrenal nodules 1 cm or greater with matching lateralization on adrenal vein sampling (AVS)
You will not qualify if you...
- Individuals with chronic kidney disease (estimated glomerular filtration rate <40 mL/min/1.73m2)
- Individuals with uncontrolled severe hypertension (>180/110 mmHg)
- Individuals with severe uncontrolled diabetes
- Individuals with suspected or proven hypercortisolism such as cortisol-secreting adrenal adenoma
- Individuals with liver diseases such as hepatic adenoma or focal nodular hyperplasia
- Allergy to intravenous contrast
- Coagulopathy
- Use of chronic corticosteroids
- Pregnancy or lactation
- Individuals with pheochromocytoma
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Calgary
Calgary, Alberta, Canada
Actively Recruiting
Research Team
A
Alexander Leung, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here